RFK Jr.'s peptide push could unleash risky drugs STAT First Opinion The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Peptides may soon be easier to get amid RFK Jr.'s push, but experts warn of risks The biggest peptide story of 2026 may not be a new study. It may be the FDA review calendar. BPC 157, TB 500, MOTS c, Semax, and other peptides are headed into FDA advisory review An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs ProPublica